IRhythm Technologies, Inc. (IRTC) Q3 2024 Earnings Call Transcript Summary
IRhythm Technologies, Inc. (IRTC) Q3 2024 Earnings Call Transcript Summary
Adjusted net loss for Q3 2024 was approximately negative $39.2 million or a loss of $1.26 per share.The following is a summary of the IRhythm Technologies, Inc. (IRTC) Q3 2024 Earnings Call Transcript:
以下是IRhythm Technologies, Inc. (IRTC) 2024年第三季度業績會交流摘要：
Financial Performance:
金融業績：
iRhythm reported Q3 revenue of $147.5 million, marking an 18.4% year-over-year growth.
Gross margin for Q3 was 68.8%, which reflects ongoing benefits from operational efficiency and reduced costs related to excess inventory.
Adjusted net loss for Q3 2024 was approximately negative $39.2 million or a loss of $1.26 per share.
iRhythm報告2024年第三季度營業收入爲14750萬美元，同比增長18.4%。
第三季度的毛利率爲68.8%，反映了持續受益於運營效率和減少與過量庫存相關成本。
2024年第三季度調整後的淨虧損約爲負3920萬美元，或每股1.26美元的虧損。
Business Progress:
業務進展：
iRhythm celebrated over 1 million patients registered for the Zio monitor and significant expansions in both domestic and international markets, particularly in the United Kingdom and European countries such as Austria, the Netherlands, Switzerland, and Spain.
Entered a technology licensing agreement with BioIntelliSense to expand the capabilities of Zio products to include multi-parameter sensing.
Launched the latest Zio Suite update, enhancing user experience and workflow for healthcare providers.
Achieved substantial milestones in regulatory compliance, including FDA clearance for one of the 510(k) applications for the Zio AT system.
iRhythm慶祝Zio心臟監測儀注冊用戶超過100萬，並在國內和國際市場實現了重要擴展，特別是在英國和歐洲國家如奧地利、荷蘭、瑞士和西班牙。
與BioIntelliSense達成技術許可協議，以擴展Zio產品的能力，包括多參數傳感。
推出了最新的Zio Suite更新，增強了醫療保健提供者的用戶體驗和工作流程。
在監管合規方面取得了實質性里程碑，其中Zio At系統的510(k)申請之一獲得了FDA的清除。
Opportunities:
機會：
The continued expansion into international markets, particularly with recent entry into European countries and regulatory approval in Japan, presents significant growth potential.
The partnership with BioIntelliSense for multi-parameter monitoring capabilities positions iRhythm to access broader clinical applications and markets in the future.
持續擴張國際市場，特別是最近進入歐洲國家並在日本獲得監管批准，展現了巨大的增長潛力。
與BioIntelliSense合作實現了多參數監測能力，爲iRhythm未來訪問更廣泛的臨床應用和市場奠定基礎。
Risks:
風險：
Delays and challenges in regulatory approval processes, particularly highlighted by the postponed regulatory submissions for the Zio MCT system in response to recent FDA observations.
Ongoing need for extensive remediation efforts to comply with FDA regulations, impacting operational focus and financial resources.
監管批准流程中的延誤和挑戰，尤其是由於最近FDA觀察結果而推遲了Zio MCt系統的監管提交。
需要進行大量糾正工作以遵守FDA法規，影響了運營重點和財務資源。
Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示：如需更全面的詳情，請參閱投資人關係網站。本文僅供投資者參考，不作任何指引或建議。
譯文內容由第三人軟體翻譯。
